Orexo AB: First Patient Dosed in New Phase III Study Targeted Towards a Future Clinical Indication Expansion for Zubsolv

Published: Jun 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (STO:ORX) announces today that the first patient has been dosed with Zubsolv in a phase III study for a new clinical indication for Zubsolv. Currently all buprenorphine/naloxone combination products licensed in the US are indicated for maintenance treatment only. Following review by the United States Food and Drug Administration (FDA), Orexo has initiated a phase III study, which once completed successfully, will be the basis for an application to expand the Zubsolv label with a clinical indication that encompass induction of treatment. Zubsolv is a novel sublingual formulation of buprenorphine and naloxone, with projected approval for use in maintenance treatment of opioid dependence by the FDA by July 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news